Eli Lilly's (LLY) CEO says that the number of people engaging with the Lilly direct has increased to over 1mln patients in 2025

• Eli Lilly (LLY) exec says that price is expected to drag on growth in the low to mid teens range in 2026.
• Company also plans to launch its obesity pill outside the US in 2027.

Eli Lilly's announcement about its engagement with over 1 million patients suggests strong demand for its offerings, which reflects positively on its future growth trajectory. However, the CEO's mention of pricing pressures expected to moderate growth in the low to mid-teens for 2026 indicates potential headwinds that investors should be aware of. Additionally, plans to launch the obesity pill internationally could create new revenue streams, but the timing and execution will be key.